{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:08:34Z","timestamp":1777950514806,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Standard neoadjuvant therapy for early HER2-positive breast cancer consists of 18 weeks of carboplatin, docetaxel, trastuzumab, and pertuzumab. However, treatment intensity may limit feasibility in frail patients and exceed therapeutic needs in selected early-stage disease. We report here real-world clinical outcomes of patients receiving a shortened 12-week neoadjuvant regimen of weekly paclitaxel and carboplatin administered with trastuzumab and pertuzumab (12wTCHP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of patients with HER2-positive breast cancer treated with neoadjuvant 12wTCHP in a single tertiary medical center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of forty-four eligible patients receiving 12wTCHP, 41 had invasive ductal carcinoma (IDC, 93%), and 64% were ER-positive. The majority of the cohort had stage IIA (73%, median age 59\u00a0years), while the remainder had stage IIB\u00a0or\u00a0stage\u00a0III disease and were significantly older (median age 64 and 76\u00a0years,\u00a0respectively;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007). Grade 3\u20134 neutropenia (20%) and diarrhea (19%) were the most frequent toxicities. No treatment-related deaths occurred. Pathological complete response (pCR) rate was 61%: 54% in ER-positive tumors and 75% in ER-negative tumors (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.208). After a median follow-up of 30 months, only two recurrences (5%) were observed. None of the 30 patients with stage IIA IDC had disease recurrence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this retrospective cohort study, neoadjuvant 12wTCHP was well tolerated and associated with high pCR and low early recurrence rates. These findings are hypothesis-generating and support further evaluation of de-escalated 12wTCHP regimen in selected patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-026-07942-4","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:58:05Z","timestamp":1775869085000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant twelve weekly paclitaxel\u2013carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer"],"prefix":"10.1007","volume":"217","author":[{"given":"Yasmin","family":"Leshem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inbal","family":"Golomb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asia","family":"Zubkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Bar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shlomit","family":"Strulov Shachar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shir","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noa","family":"Keren-Khadmy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Sonnenblick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"7942_CR1","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684. https:\/\/doi.org\/10.1056\/NEJMoa052122","journal-title":"N Engl J Med"},{"key":"7942_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273\u20131283. https:\/\/doi.org\/10.1056\/NEJMoa0910383","journal-title":"N Engl J Med"},{"key":"7942_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G von Minckwitz","year":"2017","unstructured":"von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G et al (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377:122\u2013131. https:\/\/doi.org\/10.1056\/NEJMoa1703643","journal-title":"N Engl J Med"},{"key":"7942_CR4","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1634\/theoncologist.2013-0091","volume":"18","author":"H-J Au","year":"2013","unstructured":"Au H-J, Eiermann W, Robert NJ, Pienkowski T, Crown J, Martin M et al (2013) Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. Oncologist 18:812\u2013818. https:\/\/doi.org\/10.1634\/theoncologist.2013-0091","journal-title":"Oncologist"},{"key":"7942_CR5","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","volume":"19","author":"MS van Ramshorst","year":"2018","unstructured":"van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentj\u00e9 VO et al (2018) Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 19:1630\u20131640. https:\/\/doi.org\/10.1016\/S1470-2045(18)30570-9","journal-title":"Lancet Oncol"},{"key":"7942_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S1470-2045(23)00051-7","volume":"24","author":"SM Tolaney","year":"2023","unstructured":"Tolaney SM, Tarantino P, Graham N, Tayob N, Par\u00e8 L, Villacampa G et al (2023) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol 24:273\u2013285. https:\/\/doi.org\/10.1016\/S1470-2045(23)00051-7","journal-title":"Lancet Oncol"},{"key":"7942_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1406281","volume":"372","author":"SM Tolaney","year":"2015","unstructured":"Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK et al (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372:134\u2013141. https:\/\/doi.org\/10.1056\/NEJMoa1406281","journal-title":"N Engl J Med"},{"key":"7942_CR8","doi-asserted-by":"publisher","first-page":"8795","DOI":"10.1245\/s10434-024-16087-x","volume":"31","author":"N Muppidi","year":"2024","unstructured":"Muppidi N, Adesoye T, Yi M, Sun SX, Chavez-MacGregor M, Singh P et al (2024) Clinical outcomes in patients with early stage node-negative HER2-positive breast cancer receiving upfront surgery or neoadjuvant systemic therapy. Ann Surg Oncol 31:8795\u20138801. https:\/\/doi.org\/10.1245\/s10434-024-16087-x","journal-title":"Ann Surg Oncol"},{"key":"7942_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00433-x","volume":"8","author":"SJ An","year":"2022","unstructured":"An SJ, Duchesneau ED, Strassle PD, Reeder-Hayes K, Gallagher KK, Ollila DW et al (2022) Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2\/N0 HER2+ breast cancer. NPJ Breast Cancer 8:65. https:\/\/doi.org\/10.1038\/s41523-022-00433-x","journal-title":"NPJ Breast Cancer"},{"key":"7942_CR10","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1200\/JCO.1984.2.11.1281","volume":"2","author":"W Hryniuk","year":"1984","unstructured":"Hryniuk W, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281\u20131288. https:\/\/doi.org\/10.1200\/JCO.1984.2.11.1281","journal-title":"J Clin Oncol"},{"key":"7942_CR11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejca.2017.04.001","volume":"79","author":"SJ Schraa","year":"2017","unstructured":"Schraa SJ, Frerichs KA, Agterof MJ, Hunting JCB, Los M, de Jong PC (2017) Relative dose intensity as a proxy measure of quality and prognosis in adjuvant chemotherapy for breast cancer in daily clinical practice. Eur J Cancer 79:152\u2013157. https:\/\/doi.org\/10.1016\/j.ejca.2017.04.001","journal-title":"Eur J Cancer"},{"key":"7942_CR12","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/annonc\/mdx494","volume":"28","author":"UA Nitz","year":"2017","unstructured":"Nitz UA, Gluz O, Christgen M, Grischke E-M, Augustin D, Kuemmel S et al (2017) De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+\/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab \u00b1 weekly paclitaxel. Ann Oncol Off J Eur Soc Med Oncol 28:2768\u20132772. https:\/\/doi.org\/10.1093\/annonc\/mdx494","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"7942_CR13","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/S1470-2045(21)00122-4","volume":"22","author":"JM P\u00e9rez-Garc\u00eda","year":"2021","unstructured":"P\u00e9rez-Garc\u00eda JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P et al (2021) Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol 22:858\u2013871. https:\/\/doi.org\/10.1016\/S1470-2045(21)00122-4","journal-title":"Lancet Oncol"},{"key":"7942_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(24)00104-9","volume":"25","author":"A van der Voort","year":"2024","unstructured":"van der Voort A, Louis FM, van Ramshorst MS, Kessels R, Mandjes IA, Kemper I et al (2024) MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study. Lancet Oncol 25:603\u2013613. https:\/\/doi.org\/10.1016\/S1470-2045(24)00104-9","journal-title":"Lancet Oncol"},{"key":"7942_CR15","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1001\/jamaoncol.2023.0646","volume":"9","author":"O Gluz","year":"2023","unstructured":"Gluz O, Nitz UA, Christgen M, Kuemmel S, Holtschmidt J, Schumacher J et al (2023) Efficacy of endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy in patients with hormone receptor-positive\/ERBB2-positive early breast cancer: the neoadjuvant WSG-TP-II randomized clinical trial. JAMA Oncol 9:946\u2013954. https:\/\/doi.org\/10.1001\/jamaoncol.2023.0646","journal-title":"JAMA Oncol"},{"key":"7942_CR16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1200\/JCO.2025.43.16_suppl.501","volume":"43","author":"NM Tung","year":"2025","unstructured":"Tung NM, Zhao F, DeMichele A, Prat A, Winer EP, Wright J et al (2025) Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II\/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the EA1181\/CompassHER2 pCR trial. J Clin Oncol 43:501\u2013501. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.501","journal-title":"J Clin Oncol"},{"key":"7942_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","volume":"89","author":"A Schneeweiss","year":"2018","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Waldron-Lynch M et al (2018) Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer Oxf Engl 1990 89:27\u201335. https:\/\/doi.org\/10.1016\/j.ejca.2017.10.021","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"7942_CR18","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1001\/jamaoncol.2021.1371","volume":"7","author":"A van der Voort","year":"2021","unstructured":"van der Voort A, van Ramshorst MS, van Werkhoven ED, Mandjes IA, Kemper I, Vulink AJ et al (2021) Three-year follow-up of neoadjuvant chemotherapy with or without anthracylines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial. JAMA Oncol 7:978\u2013984. https:\/\/doi.org\/10.1001\/jamaoncol.2021.1371","journal-title":"JAMA Oncol"},{"key":"7942_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","volume":"19","author":"SA Hurvitz","year":"2018","unstructured":"Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang C-S, Thompson AM et al (2018) Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 19:115\u2013126. https:\/\/doi.org\/10.1016\/S1470-2045(17)30716-7","journal-title":"Lancet Oncol"},{"key":"7942_CR20","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jamaoncol.2021.1932","volume":"7","author":"T Hatschek","year":"2021","unstructured":"Hatschek T, Foukakis T, Bj\u00f6hle J, Lekberg T, Fredholm H, Elinder E et al (2021) Neoadjuvant trastuzumab, pertuzumab, and docetaxel vs trastuzumab emtansine in patients with ERBB2-positive breast cancer: a phase 2 randomized clinical trial. JAMA Oncol 7:1360\u20131367. https:\/\/doi.org\/10.1001\/jamaoncol.2021.1932","journal-title":"JAMA Oncol"},{"key":"7942_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3692","volume":"6","author":"Z Shao","year":"2020","unstructured":"Shao Z, Pang D, Yang H, Li W, Wang S, Cui S et al (2020) Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial. JAMA Oncol 6:e193692. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3692","journal-title":"JAMA Oncol"},{"key":"7942_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11912-014-0428-7","volume":"17","author":"WM Sikov","year":"2015","unstructured":"Sikov WM (2015) Assessing the role of platinum agents in aggressive breast cancers. Curr Oncol Rep 17:3. https:\/\/doi.org\/10.1007\/s11912-014-0428-7","journal-title":"Curr Oncol Rep"},{"key":"7942_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1200\/JCO.2010.28.6450","volume":"29","author":"V Valero","year":"2011","unstructured":"Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G et al (2011) Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 29:149\u2013156. https:\/\/doi.org\/10.1200\/JCO.2010.28.6450","journal-title":"J Clin Oncol"},{"key":"7942_CR24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA500","author":"H-F Gao","year":"2025","unstructured":"Gao H-F, Li W, Wu Z, Dong J, Cao Y, Zhao Y et al (2025) De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): a multicentre, open-label, randomised, phase 3 trial. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA500","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07942-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07942-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07942-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:36:27Z","timestamp":1777880187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07942-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7942"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07942-4","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amir Sonnenblick reports a relationship with Eli Lilly that includes: consulting or advisory. Amir Sonnenblick reports a relationship with Novartis that includes: consulting or advisory, funding grants, and speaking and lecture fees. Amir Sonnenblick reports a relationship with Roche that includes: consulting or advisory, funding grants, speaking and lecture fees, and travel reimbursement. Amir Sonnenblick reports a relationship with Stemline Therapeutics Inc that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Amir Sonnenblick reports a relationship with Pfizer that includes: travel reimbursement. Amir Sonnenblick reports a relationship with Progenetics that includes: speaking and lecture fees. Amir Sonnenblick reports a relationship with Gilead Sciences Inc that includes: funding grants and speaking and lecture fees. Amir Sonnenblick reports a relationship with Merck & Co Inc that includes. Yasmin Leshem reports a relationship with Novartis that includes: consulting or advisory and speaking and lecture fees. Yasmin Leshem reports a relationship with Eli Lilly that includes: consulting or advisory. Yasmin Leshem reports a relationship with Gilead Sciences Inc that includes: travel reimbursement. Yael Bar reports a relationship with Stemline Therapeutics Inc that includes: speaking and lecture fees. Yael Bar reports a relationship with Eli Lilly and Company that includes: consulting or advisory and speaking and lecture fees. Yael Bar reports a relationship with Roche that includes: speaking and lecture fees and travel reimbursement. Yael Bar reports a relationship with Gilead Sciences Inc that includes: speaking and lecture fees. Yael bar reports a relationship with Pfizer Inc that includes: speaking and lecture fees. Yael Bar reports a relationship with Novartis that includes: consulting or advisory and speaking and lecture fees. Yael Bar reports a relationship with Astra zeneca that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}